TGF-β1/Smad3-IN-1

• UNSPSC Description:

  TGF-β1/Smad3-IN-1 (Compound 5aa) is an inhibitor of the TGF-β1/Smad3 signaling pathway(IC50=1.07 μM). TGF-β1/Smad3-IN-1 possesses antifibrotic activity and oral potency[1].

• Target Antigen:

  TGF-beta/Smad

• Type:

  Reference compound

• Related Pathways:

  Stem Cell/Wnt;TGF-beta/Smad

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/tgf-β1-smad3-in-1.html

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C(C1=CC(NC/2=O)=C(C=C1)C2=C(NC3=CC=C(N4CCN(C)CC4)C=C3)/C5=CC=CC=C5)OC.CCS(=O)(O)=O

• Molecular Weight:

  578.68

• References & Citations:

  [1]An B, et al. Inhibition of TGF-β1/Smad3 signaling by compound 5aa: A potential treatment for idiopathic pulmonary fibrosis. Bioorg Chem. 2024 Apr 16;147:107374.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported